BioCentury
ARTICLE | Company News

Vernalis, RedoxTherapeutics deal

October 27, 2014 7:00 AM UTC

Vernalis granted RedoxTherapeutics exclusive, worldwide rights to develop and commercialize vipadenant ( V2006) for immuno-oncology indications. Vernalis and Biogen Idec Inc. (NASDAQ:BIIB, Weston, Ma...